Publicaciones científicas

27 Publicaciones científicas disponibles

  • A phenotypic map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites

    12 de enero de 2019 | Revista: Histopathology

    Martins-Filho SN (1,2), Alves VAF (1,3), Wakamatsu A (3), Maeda M (4), Craig AJ (4), Assato AK (3), Villacorta-Martin C (4), D'Avola D (5), Labgaa I (4,6), Carrilho FJ (7), Thung SN (8), Villanueva A (4,9).

    (1) Departamento de Patologia, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil.
    (2) Department of Pathology and Laboratory Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
    (3) Laboratorio de Patologia do Fígado LIM 14, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
    (4) Liver Cancer Research Program, Division of Liver Diseases, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    (5) Liver Unit, Clínica Universidad de Navarra, Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (Ciberehd), Pamplona, Spain.
    (6) Department of Visceral Surgery, Lausanne University Hospital CHUV, Switzerland.
    (7) Departamento de Gastroenterologia, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil.
    (8) Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    (9) Division of Hematology and Medical Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.


  • A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma

    9 de abril de 2018 | Revista: Oncogene

    Labgaa I (1,2), Villacorta-Martin C (1), D'Avola D (1,3), Craig AJ (1), von Felden J (1,4), Martins-Filho SN (1,5,6), Sia D (1), Stueck A (7,8), Ward SC (7), Fiel MI (7), Mahajan M (9), Tabrizian P (1,10), Thung SN (7), Ang C (11), Friedman SL (1), Llovet JM (1,12,13), Schwartz M (1,10), Villanueva A (14,15).

    (1) Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, USA.
    (2) Department of Visceral Surgery, Lausanne University Hospital CHUV, Lausanne, Switzerland.
    (3) Liver Unit and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Clinica Universidad de Navarra, Pamplona, Spain.
    (4) I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    (5) Department of Pathology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
    (6) Department of Pathology and Laboratory Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
    (7) Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, USA.
    (8) Department of Pathology, Dalhousie University, Halifax, NS, Canada.
    (9) Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.
    (10) Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, USA.
    (11) Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology and Medical Oncology, New York, USA.
    (12) Liver Cancer Translational Research Laboratory, BCLC Group, IDIBAPS, CIBEREHD, Hospital Clinic, Universitat de Barcelona, Catalonia, Spain.
    (13) Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
    (14) Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, USA.
    (15) Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology and Medical Oncology, New York, USA.


  • NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma

    21 de abril de 2017 | Revista: Oncotarget

    Neri L (1), Lasa M (1), Elosegui-Artola A (2), D'Avola D (3,4), Carte B (1), Gazquez C (1), Alve S (5), Roca-Cusachs P (2,6), Iñarrairaegui M (3,4), Herrero J (3,4), Prieto J (1,3), Sangro B (3,4), Aldabe R (1,4).

    (1) Gene Therapy and Regulation of Gene Expression Program, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona, Spain.
    (2) Institute for Bioengineering of Catalonia, Barcelona, Spain.
    (3) Liver Unit, Clínica Universidad de Navarra, Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (Ciberehd), Pamplona, Spain.
    (4) Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
    (5) Department of Biology, CBMA-Centre of Molecular and Environmental Biology, University of Minho, Campus de Gualtar, Braga, Portugal.
    (6) University of Barcelona, Barcelona, Spain.


  • Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation

    17 de marzo de 2017 | Revista: Annals of Transplantation

    Aguiar D (1), Martínez-Urbistondo D (1), D'Avola D (2,3,4), Iñarrairaegui M (2,3,4), Pardo F (3,4,5), Rotellar F (3,4,5), Sangro B (6,3,4), Quiroga J (6,3,4), Herrero JI (2,3,4).

    (1) Department of Internal Medicine, Clinica Universidad de Navarra, Pamplona, Navarra, Spain.
    (2) Liver Unit, Clinica Universidad de Navarra, Pamplona, Navarra, Spain.
    (3) Network Center of Biomedical of Liver and Digestive Diseases Hepáticas y (CIBERehd), Pamplona, Navarra, Spain.
    (4) Institute of Health Research of Navarra (IdiSNA), Pamplona, Navarra, Spain.
    (5) Department of Surgery, Clinica Universidad de Navarra, Pamplona, Navarra, Spain.
    (6) Liver Unite, Clinica Universidad de Navarra, Pamplona, Navarra, Spain.